Skip to main navigation Skip to search Skip to main content

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

  • Elisabeth I. Heath
  • , Melvin Gaskins
  • , Henry C. Pitot
  • , Roberto Pili
  • , Winston Tan
  • , Robert Marschke
  • , Glenn Liu
  • , David Hillman
  • , Fazlul Sarkar
  • , Shijie Sheng
  • , Charles Erlichman
  • , Percy Ivy
  • Wayne State University
  • Howard University
  • Mayo Clinic Rochester, MN
  • Mayo Clinic Florida
  • Mayo Clinic Arizona
  • University of Wisconsin-Madison
  • National Institutes of Health

Research output: Contribution to journalArticlepeer-review

53 Scopus citations
Original languageEnglish
Pages (from-to)138-141
Number of pages4
JournalClinical Prostate Cancer
Volume4
Issue number2
DOIs
StatePublished - Sep 2005

Keywords

  • Androgen receptor
  • Hsp90
  • Interleukin-6
  • Maspin

Fingerprint

Dive into the research topics of 'A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this